A recent study suggests that patients who come off new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Findings released in a leading health publication demonstrates that while obese people can lose a large proportion of their total mass while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Users buying such drugs must be aware of the danger of fast rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
That rate of recovery implies a return to original mass in about one and a half years.
Comparing Treatments
The research, which looked at dozens of trials involving thousands of participants, compared the effects of GLP-1 agonists with older methods.
Scientists emphasize that people who shed pounds through diet and exercise typically experience a more gradual weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Experts propose the mode of action of the injections is key to understanding the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making overeating far more likely."
An Ongoing Condition?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals argue that, considering the likelihood of weight regain, the treatment might need to be life-long.
This view is supported by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," similar to managing conditions like hypertension.
User Accounts
Individuals who have come off the medication describe a powerful resurgence of cravings.
"It was like a switch that goes on and you're instantly extremely hungry," said an individual.
The struggle is compounded if patients have not established permanent dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, experts emphasize that while these medications are effective tools for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on combined behavioural changes.
